Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00416845
Recruitment Status : Completed
First Posted : December 28, 2006
Last Update Posted : June 4, 2010
Information provided by:

Brief Summary:
This study is designed to assess the effects of two doses of FTY720 on lung (pulmonary) and cardiac (heart) functions in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: FTY720 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Parallel Group, Double-blind, Placebo Controlled, 14 Days Multiple-dose Treatment to Assess the Pulmonary and Cardiac Pharmacodynamics of FTY720 (0.5 and 1.25 mg) in Healthy Volunteers
Study Start Date : October 2006
Actual Primary Completion Date : March 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Effects of two doses of FTY720 on lung and cardiac (heart) functions in healthy volunteers.

Secondary Outcome Measures :
  1. Treatment initiation effect on heart rhythm.
  2. Duration of dynamic effect on heart rate and rhythm.
  3. Treatment initiation effect and duration of this effect on cardiac output and stroke volume.
  4. Treatment initiation effect and the duration of this effect on pulmonary function with methacholine challenge.
  5. Pharmacodynamic effect on absolute lymphocyte count.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, non-smoking,(ie. 6 months w/o the use of nicotine or nicotine containing products), male or female subjects.
  • Female subjects must be either surgically sterilized (including bilateral tubal ligation) at least 6 months or post-menopausal. Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion and menopause will be confirmed by a plasma FSH level of >40 IU/L.
  • Male subjects agree to refrain from sperm donation from check-in until 30 days beyond the conclusion of all study events.
  • Male subjects must agree to the use of condoms with spermicide with sexual intercourse from 14 days prior to check-in until 30 days beyond the last dose of study drug.
  • Resting heart rate ≥ 50 beats per minute (bpm)

Exclusion Criteria:

  • History or presence of any clinically significant events, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • Subjects with systolic blood pressure < 90 mmHg or diastolic blood pressure < 50 mmHg
  • Male subjects with a QTcB > 450 msec
  • Female subjects with a QTcB > 470 msec
  • Subjects with pulmonary symptoms, history of exercise-induced asthma, asthma or chronic obstructive pulmonary disease (COPD)
  • Use of any prescription drug within 1 month of starting the study
  • Positive urine screen for alcohol or drugs at screening, unless the test is shown to be falsely positive on confirmation testing.
  • Hemoglobin < 12g/dL
  • Donation of blood or significant blood loss within 56 days prior to check in.
  • Donation of plasma within 7 days prior check in.
  • Participation in an investigational study within 30 days prior to check in.
  • Positive screening test for HIV or Hepatitis B or C.
  • A past history of cigarette smoking of > 10 pack-years or use of nicotine or nicotine-containing products 6 months prior to dosing.

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00416845

United States, New Jersey
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080
Sponsors and Collaborators
Principal Investigator: Novartis Investigator site Identifier: NCT00416845     History of Changes
Other Study ID Numbers: CFTY720D2105
First Posted: December 28, 2006    Key Record Dates
Last Update Posted: June 4, 2010
Last Verified: June 2010

Keywords provided by Novartis:
pharmacodynamic effects, cardiac effects, healthy subjects, synthetic sphingosine 1 phosphate (S1P) receptor modulator
Healthy male and female subjects

Additional relevant MeSH terms:
Fingolimod Hydrochloride
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs